ABOS: Phase II data for a novel Alzheimer's antibody is expected in Q4 2024, with EBD IND in 2027
Sabirnetug, a selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected in late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027. Key milestones include robust clinical retention and advancing two EBD candidates.Ba…
Story updates
10:09:39 PM UTC
SquawkNews
Sabirnetug, a highly selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027, with two candidates in development. ALTITUDE results will validate the oligomer…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.